Repair peptides FAQ

BPC-157 systemic protocols are still viable but require 2–3× higher total doses compared to localized delivery to achieve comparable tendon outcomes. The Phase IIb trial used 250–300mcg localized versus 500–750mcg systemic daily in earlier studies. TB-500 remains effective systemically and does not benefit from localized delivery in the same way. Its mechanism (actin sequestration and cell migration) functions throughout the body, not just at injury sites.

No. Recalculate dosing frequency. Protocols written before March 2025 assume a 10-day half-life, recommending injections every 7–10 days. The corrected 6.8-day half-life means trough plasma levels drop below the therapeutic threshold by day 6–7, leaving a gap where fibroblast activity declines before the next dose. Shift to every-5-day dosing at the same per-injection dose (typically 2–2.5mg for a 70kg model). This maintains plasma concentration within the range that sustains MMP upregulation and actin sequestration throughout the healing cycle.

Don't use standard GHK-Cu for tendon repair. The data is clear that non-liposomal forms achieve insufficient bioavailability to activate collagen synthesis pathways in connective tissue. If liposomal GHK-Cu is unavailable, consider BPC-157 or TB-500 instead, both of which have established efficacy in non-liposomal forms. Attempting to create liposomal formulations in-house without sonication equipment and particle size validation will not replicate the 38–42% bioavailability reported in controlled studies.

Verify three factors before concluding non-response: reconstitution date (peptides in sterile water lose potency rapidly), injection proximity to injury site (subcutaneous administration >5cm from the affected ligament reduces local bioavailability significantly), and dosing timing relative to injury phase. BPC-157 acts primarily during the proliferative phase (days 14–56 post-injury). Administration during the inflammatory phase or late remodelling phase produces minimal effect because the cellular targets (fibroblasts, endothelial cells undergoing angiogenesis) are not yet active or have already completed their primary activity window. If all three factors are correct and response is still absent, consider TB-500 as an alternative or verify peptide purity through third-party assay.

The positive pressure created inside the vial forces peptide-laden solution back through the needle, contaminating the needle exterior and reducing dose accuracy. To prevent this: insert the needle through the stopper, invert the vial completely, draw the solution without injecting air first, and withdraw at a 45-degree angle. If you've already injected air, wipe the needle with an alcohol swab before injection to remove exterior contamination. But note that repeated air injection degrades the rubber stopper over time, increasing particulate contamination risk in subsequent draws.

Refuse the shipment and request replacement with temperature verification. Peptides exposed to ambient temperature (>25°C) for more than 6 hours undergo irreversible tertiary structure disruption. The amino acid sequence remains intact but the bioactive conformation is destroyed. This cannot be detected visually or reversed through refrigeration. Temperature-logging cold packs or data loggers are the only reliable verification that the peptide maintained required storage temperature throughout transit. Real Peptides includes temperature verification with every shipment specifically to eliminate this variable in research reproducibility.